{
    "Clinical Trial ID": "NCT00450723",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Sentinel Lymph Node Biopsy",
        "[Not Specified]"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed breast cancer",
        "  Stage I or II disease (T1-T2, N0, M0/MX disease)",
        "  No chest wall invasion by tumor (T3 disease)",
        "  Medially or centrally located lesion",
        "  No multicentric disease",
        "  Multifocal disease allowed",
        "  No clinically positive axillary nodes",
        "  No enlarged internal mammary nodes by CT scan",
        "  Hormone receptor status not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Male or female",
        "  Menopausal status not specified",
        "  American Society of Anesthesiologists (ASA) physical status classification 1-2",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  No other concurrent known, invasive malignancy",
        "  No known chronic pulmonary disease",
        "  No known allergy to methylene blue or isosulfan blue",
        "  PRIOR CONCURRENT THERAPY:",
        "  No prior thoracic or cardiac surgery",
        "  No prior ipsilateral chest tube placement",
        "  Contralateral chest tube placement allowed",
        "  No prior neoadjuvant chemotherapy",
        "  No prior radiotherapy to the mediastinum"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy",
        "  [Not Specified]",
        "  Time frame: 5 years",
        "Results 1: ",
        "  Arm/Group Title: Sentinel Lymph Node Biopsy",
        "  Arm/Group Description: [Not Specified]",
        "  Overall Number of Participants Analyzed: 34",
        "  Measure Type: Number",
        "  Unit of Measure: participants  31"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/34 (0.00%)"
    ]
}